Skip to main content
Equibles
CNTA logo

CNTA · Centessa Pharmaceuticals plc · Metrics

Track CNTA — free

Use CNTA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CNTA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
Rebalance outlook locked
Market Cap
$6.27B
Shares
154.73M
Volume — Avg daily vol (3M) —

CNTA metrics

38 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
—
Market cap
$6.27B

Price action

23 metrics
Price change (1W)
—
Price change (30D)
—
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
—
52-week low
—
Change from 52-week high
—
Change from 52-week low
—
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
—
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
—
Relative volume
—
Average dollar volume
—

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
154.73M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
12.9
reciprocal yield 7.8%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-4.0%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2023-11-13

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$256.69M
Net income (TTM)
−$250.64M
Trailing 12 months
Diluted EPS (TTM)
$-1.78
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
$-1.81
EBITDA per diluted share (TTM)
$-1.81
Net income per diluted share (TTM)
$-1.77
Operating cash flow per diluted share (TTM)
$-1.47
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
$1.40
Stock compensation per diluted share (TTM)
$0.24
Book value per share
$3.53

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+15.4%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-51.4%
Return on assets
-39.1%
Debt / equity
0.2
Current ratio
9.5
EBITDA (TTM)
−$255.75M
Free cash flow (TTM)
—
Quick ratio
9.5
Interest coverage
-22.7
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$166.15M
Latest balance sheet
Cash & equivalents
$62.43M
Total assets
$641.76M
Total debt
$110.44M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$208.79M
Capital expenditures (TTM)
—
R&D (TTM)
$198.67M
SG&A (TTM)
—
Stock compensation (TTM)
$33.64M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
0
13F filer change QoQ
-161
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.1%

Short interest

3 metrics
Short interest
—
Latest settlement
Days to cover
—
Short-squeeze score
—

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1847903 CUSIP 152309100 13F (30d) 13 filings 1 filers Visit website